ViroPharma Appears Quite Healthy

Tags: vphm
3 Dec 2:23am
Posted by ZacksResearch
0 Comments
Read original blog entry

ViroPharma Incorporated (VPHM) posted very strong financial results for the third quarter. Vancocin sales blew away expectations, coming in at $65.9 million, up 29%. Vancocin continues to benefit from impending treatment guideline changes and ViroPharma's new specialty salesforce.

The acquisition and approval of Cinryze greatly strengthens the company's future prospects. We expect management to be in position to launch the product in the next few weeks. Besides strong Vancocin sales and the Cinryze approval, both phase III trials on maribavir are progressing on plan.

ViroPharma Inc.'s business fundamentals are strong. Sales and earnings are outpacing expectations and the company should exit the year with over $300 million in cash on hand. We are maintaining our Buy rating with a price target of $16.

Read the full analyst report on VPHM



Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all today’s Analyst Blog entries on Zacks.com.

Comments

Back to top

Post comment

Back to top

Post a comment

Please login to post a comment

About

ZacksResearch

Zacks Investment Research is one of the most highly regarded firms in the investment industry. Our firm has long believed that that quantitative models (like the Zacks Rank) can predict stock prices more accurately than individual analysts. However we also recognize that models are most effective when they are employed by analysts who have deep fundamental knowledge of the company and its industry. Consequently Zacks Equity Research combines Zacks quantitative models with the insight provided by an experienced team of 50 analysts to create superior long term stock recommendations. Discover all their timely insight and recommendations daily on Zacks.com.

Recent Entries